Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
Active, not recruiting · NCT02522715 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, castration-resistant prostate carcinoma, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-15 | NCT02522715 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| OHSU Knight Cancer Institute | 61 |
| Oregon Health and Science University | 244 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| OHSU Knight Cancer Institute | Portland | United States | 69 |
| Portland VA Medical Center | Portland | United States | 23 |
| Seattle Cancer Care Alliance | Seattle | United States | 36 |